From Evidence to Effectiveness: Implications of the Randomized Trial to Prevent Vascular Events in HIV Study for People With HIV in Low- and Middle-Income Settings

Clin Infect Dis. 2024 Jun 14;78(6):1401-1402. doi: 10.1093/cid/ciad702.

Abstract

The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) study found a 35% reduction in major adverse cardiovascular events for people with human immunodeficiency virus who received daily pitavastatin. However, how this evidence will change practice is far from certain. Here, we outline evidence gaps and political and healthcare delivery challenges that will need to be addressed for REPRIEVE to offer public health benefits in low- and middle-income countries.

Keywords: HIV; cardiovascular disease; integrated care.

MeSH terms

  • Cardiovascular Diseases / prevention & control
  • Developing Countries*
  • HIV Infections* / prevention & control
  • Humans
  • Quinolines / administration & dosage
  • Quinolines / therapeutic use
  • Randomized Controlled Trials as Topic

Substances

  • Quinolines
  • pitavastatin